down arrow

AN2 Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0373261058
USD
1.14
0.01 (0.88%)

Dec 18

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.111.23

52 Week

1.011.55
Valuation
Technical
Day's Volume

CASH

39.73 k

Shareholding (Mar 2025)

FII

3.34%

Held by 25 FIIs

DII

74.73%

Held by 10 DIIs

Promoter

14.59%

How big is AN2 Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, AN2 Therapeutics, Inc. has a market capitalization of 35.61 million and reported net sales of 0.00 million with a net profit of -45.36 million over the last four quarters. As of Dec 24, the company's shareholder's funds were 81.85 million, and total assets were 92.09 million.

As of Jun 18, AN2 Therapeutics, Inc. has a market capitalization of 35.61 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a consolidated net profit of -45.36 million during the same period.<BR><BR>As of Dec 24, the company's shareholder's funds were 81.85 million, and total assets amounted to 92.09 million.

Read More

What does AN2 Therapeutics, Inc. do?

22-Jun-2025

AN2 Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $11 million and a market cap of $35.61 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -58.80%.

Overview: <BR>AN2 Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -11 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 35.61 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.91 <BR>Return on Equity: -58.80% <BR>Price to Book: 0.49<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is AN2 Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, AN2 Therapeutics, Inc. shows a neutral trend with mixed indicators, mildly bullish on weekly MACD and KST but bearish on daily moving averages, while outperforming the S&P 500 recently but having a negative year-to-date return, suggesting a cautious investment approach.

As of 11 September 2025, the technical trend for AN2 Therapeutics, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed indicators influencing this position. The weekly MACD and KST are mildly bullish, while the daily moving averages are mildly bearish. The Bollinger Bands show a bullish signal on the weekly timeframe but a mildly bearish signal on the monthly. The Dow Theory indicates a mildly bullish trend on both weekly and monthly timeframes. <BR><BR>In terms of performance, AN2 Therapeutics has outperformed the S&P 500 over the past week and month, with returns of 1.57% and 15.18%, respectively, compared to 1.05% and 2.33% for the index. However, the year-to-date return is negative at -6.52%, contrasting with the S&P 500's positive return of 12.22%. Overall, the mixed signals suggest a cautious approach.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 33 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.91

stock-summary
Return on Equity

-51.05%

stock-summary
Price to Book

0.47

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-6 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.63%
0%
-11.63%
6 Months
3.64%
0%
3.64%
1 Year
-12.98%
0%
-12.98%
2 Years
-94.46%
0%
-94.46%
3 Years
-88.36%
0%
-88.36%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

AN2 Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
14.55%
EBIT to Interest (avg)
-56.77
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.91
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.47
EV to EBIT
0.69
EV to EBITDA
0.69
EV to Capital Employed
-5.26
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-58.80%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 10 Schemes (7.35%)

Foreign Institutions

Held by 25 Foreign Institutions (3.34%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 54.86% vs 8.86% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.20",
          "val2": "-15.90",
          "chgp": "54.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.50",
          "val2": "-14.40",
          "chgp": "54.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 20.71% vs -57.80% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-54.60",
          "val2": "-69.60",
          "chgp": "21.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-51.30",
          "val2": "-64.70",
          "chgp": "20.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-7.20
-15.90
54.72%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-6.50
-14.40
54.86%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 54.86% vs 8.86% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-54.60
-69.60
21.55%
Interest
0.00
0.00
Exceptional Items
-2.20
0.00
Consolidate Net Profit
-51.30
-64.70
20.71%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 20.71% vs -57.80% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About AN2 Therapeutics, Inc. stock-summary
stock-summary
AN2 Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."